Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab for Pancreatic Cancer with Effusions
NCT07230301Phase 2Not yet recruiting
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in pancreatic cancer (PC). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07230301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230301.